VRTX · PEAD → 0

Vertex Pharma reported Q2 2026 EPS of $4.20 on 2026-08-03 (after market close), beating the $4.15 consensus by $0.05 (+1.2%).

Print-day reaction was -1.3%, as VRTX closed at 470.72 versus the prior close of 477.10, unwinding the pre-earnings open gap and closing below the T-1 reference. The overnight gap to the T+1 open was a modest +0.12%, suggesting no meaningful after-hours continuation in either direction. Over the following two trading sessions (T+1 through T+3), price drifted +1.1%, partially recovering the initial-day decline without fully reversing it. Cumulative abnormal return of -1.4% versus SPY.US sits inside the ±3% neutral band, yielding a PEAD verdict of none with zero conviction; no drift signal is active through 2026-10-29.